Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation

Xlife Sciences AG / Key word(s): ESG
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
19.12.2024 / 07:00 CET/CEST

Zurich, 19^th of December 2024: Xlife Sciences AG (SIX: XLS) today announced the release of its 2023 ESG Report, marking another milestone in the company’s journey to integrate sustainability and responsible business practices across its operations and project companies. The report, developed in accordance with GRI Standards, provides a transparent and comprehensive overview of Xlife Sciences AG’s environmental, social, and governance (ESG) performance for the reporting year.

This year’s report reflects the continued progress made across Xlife Sciences AG’s diverse portfolio, covering 9 key project companies and Xlife Sciences AG, selected based on operational maturity, employee engagement, and strategic impact. By aligning its sustainability reporting with internationally recognized standards, Xlife Sciences AG underscores its mission to drive innovation while fostering societal value and environmental responsibility.

David L. Deck, President of the Board of Directors, commented: «Sustainability is not just a goal for us – it is the foundation of our operations. At Xlife Sciences AG, we combine innovation and responsibility to ensure that our growth creates lasting value for society and the environment. This year’s ESG report reflects our unwavering commitment to embedding these principles into our corporate DNA.»

To strengthen its reporting and streamline ESG data collection, Xlife Sciences collaborated with Generation Impact Global SA, a leading provider of ESG solutions. Anna Shpak, CEO and Founder of Generation Impact Global SA, stated: «We are proud to provide our ESG solution to Xlife Sciences AG, supporting their commitment to sustainability and responsible innovation. By leveraging our tools, Xlife Sciences AG can seamlessly consolidate non-financial data, create comprehensive ESG reports, and drive meaningful improvements across their portfolio. This collaboration highlights the importance of integrating ESG principles into the foundation of forward-thinking companies like Xlife Sciences AG.»

Key Highlights of the 2023 ESG Report

• Alignment with GRI Standards to enhance transparency and accountability.
• Progress in gender diversity, employee development, and innovation initiatives across 9 project companies.
• Reduction in environmental impact through optimized energy use and waste minimization practices.
• Focused commitment to ethical research and responsible innovation in healthcare and biotechnology.

Désirée A. Dosch, Member of the Board of Directors and Head of the ESG Committee, emphasized: «Our second ESG report reflects our unwavering dedication to sustainability, innovation, and transparency. By embedding ESG principles into our decision-making processes and operations, we ensure that Xlife Sciences AG continues to drive meaningful change for people, society, and the environment.»

The ESG Report 2023 of Xlife Sciences AG, along with additional details about its sustainability initiatives, is now available for download at www.xlifesciences.ch/en/esg-en.

Financial calendar

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch 

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 

End of Media Release